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Objectives. To determine whether the initial benefits of spinal cord stimulation (SCS) treatment for critical limb ischemia
(CLI) persist over years.
Design. Analysis of data prospectively collected for every CLI patient receiving permanent SCS. Follow-up range 12 to
98 months (mean 46 23, median 50 months).
Population. 87 patients (28% stage III, 72%stage IV) with unreconstructable CLI due (83%) or not (17%) to atheroscle-
rosis and with an initial sitting/supine transcutaneous pO2 gradient >15 mmHg.
Methods. Assessment of actuarial patient survival (PS), limb salvage (LS) and amputation-free patient survival (AFPS).
Analysis of the impact of 15 risk factors on long-term outcomes using the Fischer’s exact test for categorical variables and
the t test for continuous variables.
Results. Follow-up was complete for patient and limb survival. A single non-atherosclerotic patient died during follow-up.
Among atherosclerotic patients PS decreased from 88% at 1y, to 76% at 3y, 64% at 5y and 57% at 7y. LS reached 84% at
1y, 78% at 2y, 75% at 3y and remained stable thereafter. Diabetes was found to affect LS (p< 0.05) and heart disease to
reduce PS (p< 0.01). AFPS was reduced in heart patients (p< 0.01), diabetics (p< 0.05) and in patients with previous
stroke (p< 0.05).
Conclusions. In CLI patients the beneficial effects of SCS persist far beyond the first year of treatment and major ampu-
tation becomes infrequent after the second year.
Keywords: Spinal cord stimulation; Critical limb ischemia; Long-term outcomes; Risk factors; Microcirculatory screening.Introduction
Beneficial effects of spinal cord stimulation (SCS) on
both ischemic pain and microcirculatory blood flow
have long been demonstrated.1e5 In contrast, the in-
fluence of SCS on limb salvage in patients with critical
limb ischemia (CLI) has been constant matter of de-
bate. Several investigators7e11 have found that the
long-term outcome of SCS treatment is closely related
with the preprocedural condition of the microcircula-
tion. SCS cannot be expected to reopen mechanically
occluded microvessels albeit it can reduce the micro-
circulatory spastic changes from CLI.3,4 Among the
multiple tests available to differentiate between
occlusive and spastic microcirculatory changes the
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has emerged as a simple and reliable test.7e9 A recent
meta-analysis of controlled trials matching 444 pa-
tients concluded to significantly higher limb salvage
at 12 months with SCS than with conservative treat-
ment.6 As for a large majority of surgical vascular
studies, however, these reports unfortunately focus
on limb salvage and quality of life at 12 months.
As a consequence accurate long-term data on limb
salvage (LS) in SCS patients are still lacking.
This study aims to review our ongoing SCS experi-
ence with follow-up extending up to 9 years, to assess
treatment durability, long-term limb and patient sur-
vival, and to investigate which factors may influence
these outcomes.
Methods
This clinical trial was conducted in a specialist
vascular unit at a university teaching hospital. Theerved.
718 P. A. Gersbach et al.demographic characteristics of the patients, degree of
ischemia, previous vascular treatments, co-morbidities,
implantation procedures as well as outcome at dis-
charge and during the follow-up period were
prospectively introduced into a database. All data
entered in the database before the end of May 2005
were reviewed and analyzed. Limb salvage was de-
fined as preservation of the heel and of the walking
capacity of the patient.
Patients with limb ischemia due to atherosclerosis
and those with non-atherosclerotic peripheral arterial
occlusive disease (PAOD) were distributed into 2 dif-
ferent groups and evaluated separately.
Patients selection and routines
Our policy is to reserve SCS treatment to the few pa-
tients who are in a stable and severely symptomatic
Fontaine’s stage III or IV12 and who don’t have ische-
mic ulcers larger than 4 centimeters. These patients
must have been deemed both unreconstructable and
medically intractable by a consensus multidisciplin-
ary decision involving angiologists, interventional
radiologists and vascular surgeons; moreover, they
must be free of major cognitive deficits and have
a minimal life expectancy of one year.
Noninvasive tests are routinely used to confirm
the arterial origin of the symptoms. Atherosclerotic
patients with ankle and toe pressure not indicative
of category 4 or 5 of the Rutherford’s classification are
excluded.13 The transcutaneous oxygenpartial pressure
(tcpO2) is measured at the dorsum of the forefoot in
the supine and sitting positions. Patients with a supine
tcpO2 over 35 mmHg, which corresponds to the lower
limit (30e50 mmHg) of the TransAtlantic Inter-Society
Consensus for diagnosing CLI,14 and those with a
positional tcpO2 difference (DtcpO2) <15 mmHg7 are
discarded. Exceptions were made in this study in 2
patients with previous controlateral amputation and
in 4 cases in which the skin conditions could not
guarantee accurate tcpO2 measurements.
A single experienced surgeon is responsible for all
implantations. Postoperative standard controls are
systematically performed in the outpatient vascular
unit after 3 weeks, 3 months 6 months, 1 year, and
on an annual basis thereafter. These controls include
an interview focusing on pain, comfort, quality of
life (QOL), degree of satisfaction and intercurrent dis-
ease. A physical examination, tcpO2 measurements in
the supine and sitting position and technical controls
of the stimulation system are repeated at each control.
Persistent acral lesions are treated by an independent
orthopedic surgeon who freely decides whether andEur J Vasc Endovasc Surg Vol 33, June 2007at which level an amputation has to be performed.
Amputations at any level above the heel are consid-
ered major.
Preparation and surgical technique
Electrodes are exclusively implanted in patients with
an INR <1.2 and a partial thromboplastin time
(PTT)<35 seconds. Subcutaneous heparin is discon-
tinued 12 hours and intravenous heparin 4 hours pre-
operatively. Antiplatelet agents are stopped 7e10
days before the planned intervention. Electrodes are
always implanted under local anesthesia and intrave-
nous antibiotics (intravenous amoxicillin/clavulanic
acid 1.2 g ttd for 48 hours or a single preoperative
shoot of 1 g Vancomycin). The epidural space is en-
tered with a Tuohy needle usually at the middle lum-
bal level and a quadripolar electrode is placed under
fluoroscopic guidance at the Th 9-Th 10 level. Stimu-
lation is begun and the electrode is manipulated until
the patient reports comfortable paresthesias in the
whole aching area. The electrode is then fixed to the
thoracolumbal fascia and connected to a percutaneous
extension cable linked to a portable external stimulat-
ing device. Subcutaneous implantation of an internal
impulse generator is proposed after 5 to 12 days of
trial stimulation to patients presenting both a substan-
tial reduction of pain symptoms and a measurable
tcpO2 increase in the supine position.
Risk factors
The impact of 15 factors on both long-term major
amputation and patient survival in atherosclerotic
patients was assessed. They were: Age, gender, Fon-
taine stage III vs lV, preoperative supine tcpO2, dia-
betes, hypertension, chronic renal failure, chronic
obstructive pulmonary disease (COPD), heart disease
requiring chronic specific treatment, atrial fibrillation,
previous stroke or transient ischemic attack (TIA),
controlateral amputation, previous sympathectomy,
previous thrombolysis and previous prostaglandine
treatment. Diseases present in less than 10% (such as
persistent smocking, cancer or HIV infection) were
considered too rare for statistical evaluation.
Statistical analysis
The main outcomes of interest were patient survival,
limb survival and amputation-free patient survival.
Survival times were calculated from the date of elec-
trode implantation to the date of death or of major
limb amputation. The Kaplan-Maier curves presented
719Long-term Outcomes of SCSat Figs. 1e3 were established with the aid of the
statistical package for the Social Science (SPSS version
8.0, Chicago IL, USA). The influence of various risk
factors on the long-term outcome was assessed by
the Fisher’s exact test for categorical variables and
by the Student t test for continuous variables; all tests
were bidirectional and p values <0.05 were considered
statistically significant. A stepwise regression analysis
was performed to predict the effect of confounding
variables on event-free survival. The statistical package
used for this analysis was JMP (Version 5.0, SAS
Institute, Cary NC).
Results
A total of 87 consecutive patients received permanent
SCS for otherwise intractable critical limb ischemia
(CLI). All were in Fontaine’s stage III or IV due to severe
atherosclerosis in 72 (83%) and to non-atherosclerotic
peripheral vascular disease in 15 (17%). For the whole
series, follow-up was complete for patients and limb
survival. It ranged from 1e9 years (mean 46 23,
median 50 months).
Of these 87 CLI patients 28% were in stage III and
72% in stage IVof the Fontaine’s classification. The de-
mographic and clinical baseline data of atherosclerotic
and non-atherosclerotic patients are shown in Table 1.
Neither death nor neurological complication oc-
curred within 30 days of surgery.
a) Non-atherosclerotic group. Non-atherosclerotic CLI
of the lower extremities was mostly due to Buerger
(8 patients) and to Raynaud (5 patients) diseases, and
to complex regional pain syndrome (CRPS) and
homocysteinemia in the remaining 2 cases. Previous
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Fig. 1. Actuarial patient survival.treatment consisted in prostaglandin therapy in five
patients and in sympathectomy in two.
Patients in the non-atherosclerotic group were
significantly younger than atherosclerotic patients.
After 3 weeks of SCS treatment all had substantially
less pain and an improved microcirculation in the
diseased area. Neither previous sympathectomy nor
previous prostaglandins treatment influenced this
outcome. The local tcpO2 value measured after 2e3
weeks of SCS in the supine position was used to guide
amputations and excisions of necrotic tissue when-
ever necessary. All amputations were limited to the
forefoot.
Survival in this small subgroup reached 93%. A
women implanted at the age of 82 years retained
her leg until her death from cardiac failure 4 years
later. There was no other fatality in this group.
In 5 patient a stimulation intensity over 4.5 volts
and in 2 others a pulse width over 700 milliseconds
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Fig. 2. Actuarial limb survival.
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Fig. 3. Actuarial amputations-free patient survival.Eur J Vasc Endovasc Surg Vol 33, June 2007
720 P. A. Gersbach et al.was required to cover the whole aching area. Such
values were never applied in the atherosclerotic
group.
Five re- interventions (29%) were necessary in 3
patients: 1 of them underwent two normal battery
replacements and its electrode had to be changed be-
cause of severe epidural fibrosis; another patient had
his battery replaced after 34 months; the third one,
a Buerger patient, became symptom-free after 8
months and remained so until his battery became
exhausted. After a period of observation we opted
for the withdrawal of the whole system, and the
patient has remained free of symptom for the last
13 months.
b) Atherosclerotic group. The main characteristics of
most patients in this group are an advanced age
(Table 1) and a poor general condition, as evidenced
by the co-morbidities listed in Table 2.
Moreover, atherosclerotic patients were all referred
to SCS at the very end-stage of the disease, with
symptoms that would have absolutely required
vascular reconstruction if feasible, and after multiple
conventional conservative and invasive treatments
had failed. Only 15 patients (21%) received SCS as
a first operative treatment. Table 3 details the treat-
ments attempted before SCS initiation.
Diasbling rest pain was present in all patients and
skin ulcers of proven arterial origin were found in
3/4 of cases (stage IV). Infection along with
Table 1. Baseline data of 87 patients
Parameter Atherosclerotic
PVD (n¼ 72)
Non-atherosclerotic
PVD (n¼ 15)
Stage III/IV 19/53 5/10
Gender F vs M 27/45 4/11
Age mean mean 75.5 7.9 years* mean 52.3 17.7*
range 49e90 y. 32e82y.
median 76 y. 48y.
Follow-up mean 47 23 months Mean 38 22 months
*p< 0.01.
Table 2. Preoperative morbidity in atherosclerotic patients
Morbid condition Nb % Comments
Diabetes 28 39% 19 under insulin
Hypertension 42 58%
Cardiopathy 36 50% previous heart
surgery in 22
Atrial fibrillation 18 25%
Stroke/TIA 15 21% permanent
deficit in 7
Controlateral.amputation 7 10% above knee in 2
Chronic renal insufficiency 16 22% dialysis in 6
COPD 10 14%
Varia 13 18% 9 carcinomas, 3 liver
cirrhoses, 1 HIVEur J Vasc Endovasc Surg Vol 33, June 2007lymphangitis and/or positive blood cultures was
present in 21 patients. All received intravenous anti-
biotics for several days before electrode placement
was considered feasible.
Patient survival (PS), limb survival (LS) and
amputation-free patient survival (AFPS) are presented
in Figs. 1e3.
Nineteen patients (26%) died after a mean period of
SCS treatment of 2.0 1.6 years (median 21 months)
due to heart failure (n¼ 12), cancer (n¼ 4), renal fail-
ure (n¼ 2) and stroke (n¼ 1). None of these deaths
was attributable to immediate or delayed complica-
tions of SCS. Neither the gender nor the age at
implantation did significantly influence mortality
(Table 4). Mean age at the time of death was 79 9.2
years.
Fifteen patients (21%) required a major amputation
during the observation period. Among them 11 were
amputated within 6 months of SCS treatment account-
ing for an early amputation rate of 15%. These early
amputations were motivated by the recurrence of
intractable pain at rest in 3 cases and by rapidly
progressing tissue necrosis or infection in the other 8.
Neither the incidence nor the time to major amputa-
tion was influenced by the Fontaine’s stage at initial
presentation.
Table 3. Previous vascular treatments in atherosclerotic patients
Type of treatment Number
Only non-invasive treatments 15 (21%)
Surgery/angioplasty 0e10/patient (mean 2.08)
Sympathectomy 16 (22.%)
Prostaglandines 15 (21%)
Thrombolysis 16 (22%)
Table 4. Influence of possible risk factors on SCS outcome in
atherosclerotic patients
Risk factor Amputation-free
patient survival
Amputation Death
Age 0.270 0.086 0.053
Gender 1.000 1.000 1.000
Stage III vs IV 0.180 0.183 0.763
Supine tcpO2 0.729 0.282 0.814
Diabetes 0.023 0.011 0.788
Hypertension 0.155 0.556 0.175
Heart disease 0.0019 0.209 0.0010
Atrial fibrillation 0.793 0.482 0.218
Stroke/TIA 0.0213 0.097 0.107
Renal failure 0.256 0.258 0.749
COPD 0.739 1.000 1.000
Controlat amput. 1.000 1.000 1.000
Sympathectomy 0.410 1.000 0.207
Prostaglandines 0.259 0.736 0.324
Thrombolysis 1.000 0.442 0.267
Stepwise regression analysis of amputation-free survival found
a probability of adverse late event of 15.2% for heart disease, of
19.6% for heart disease and diabetes and of 22.5% for patients
presenting with heart disease, diabetes an a previous stroke.
721Long-term Outcomes of SCSThe influence of demographic and clinical risk
factors on death, amputation and amputation-free
patient survival is reported in Table 4.
The preoperative tcpO2 values in the whole athero-
sclerotic group ranged from 0 to 35 mmHg in the
supine position (mean 11 11.7 mmHg, median
6.5 mmHg) and from 7 to 69 mmHg in the sitting po-
sition (mean 36 17.3, median 34.5 mmHg), allowing
to calculate a mean supine/sitting preoperative tcpO2
gradient of 24.3 12.1 mmHg (median 24 mmHg).
Systematic tcpO2 controls at 3 1 months in all
amputation-free survivors evidenced a substantial
tcpO2 increase in 46, minimal changes in 2 and dete-
rioration in 4. Table 5 compares the mean values
registered before and after 3 months of SCS in these
52 patients.
Major tcpO2 changes were infrequent beyond the
third month of treatment. The mean value obtained
at the last control in 40 amputations-free long-term
survivors was 35.5 16 mmHg (median 40) and
54.8 14.7 mmHg (median 54) in the supine and
sitting positions.
Forty-seven long-term survivors had no or very
occasional pain at rest. Three of the 4 patients with
decreased tcpO2 at 3 months and 2 patients with
increased values still complained from severe resting
pain. Among them 2 were amputated and 2 died
shortly thereafter. The last patient decided to stay
under morphinic agents until his death several
months later. The ambulation capacity of most SCS
responders was in correct adequation with their needs
and remained so beyond the third month of treat-
ment. No patient complained from ischemic pain dur-
ing home activities; pain probably due to claudication
arose after 100 to 400 meters in most patients and after
1 kilometer or more in 10%.
Thirty re-interventions were required over time
(42%). Half of them consisted in normal battery
replacement. Unexpected revision occurred in 21%
because of electrode displacement (10 cases) or rup-
ture (3 cases), premature battery depletion (1 case)
and infection (1 case). Single revision procedures
were performed in 22 patients and multiple proce-
dures in 3. Only two patients required multiple
Table 5. Effects of 3 months of SCS treatment on tcpO2 values in
52 atherosclerotic amputations-free survivors
Position Initial tcpO2
(mmHg)
tcpO2 at 3
months (mmHg)
Mean tcpO2
increase (mmHg)
supine 12.5 11.6*** 33.3 17.1*** 20.8 14.8
median 9 median 39 median 22
sitting 40.6 15.0*** 56.7 11.8*** 16.1 16
median 40 median 58 median 15.5
***p< 0.001, 2-tailed t-test.electrode and/or cable revisions; of note both were
amputees.
Discussion
This first systematic study of the long-term effects of
SCS on inoperable limb-threatening ischemia shows
that the benefits on limb salvage commonly observed
after 6 to 12 months of treatment2,6,7,11,15,18,19 persist
over time.
Selection of patients and planned follow-up
controls are prerequisite to achieve the best treatment
effect. Vascular specialists who applied tight pre-
established microcirculatory criteria selected all
patients. Hence, the results presented here cannot be
compared with those reported by neurosurgeons
anesthesiologists and pain specialists.
Current evidence indicates that the beneficial
effects of SCS on limb ischemia are mostly mediated
by early changes in the microcirculation.3,4,9,16,17
Therefore only targeted microcirculatory tests are
adequate to select potential treatment responders;
tcpO2 measurements have emerged as the most sim-
ple and reliable test to achieve this goal.7,9 A recent
review of studies using tcpO2 to select SCS candidates
has concluded that a strong selection based on a com-
bination of tcpO2 measurements substantially im-
proves limb salvage of CLI patients treated by SCS.
On balance, however, the authors also estimated that
such a stringent selection nearly halves the group of
eligible patients.18
SCS is a particularly attractive option to treat non-
atherosclerotic CLI because in such cases lesions are
usually diffuse and located in the very distal part of
the arterial system, where reconstruction is not feasi-
ble. In fact the subjective and objective results in the
15 non-atherosclerotic patients of this series were
superior to those obtained in atherosclerotic cases.
However, this series is definitely too small to allow
any accurate conclusion. From a technical point of
view the rather young age of most non-atherosclerotic
CLI patients along with the often over average stimu-
lation intensities required to cover the whole aching
area make these patients good candidates for the
newly available, albeit more expansive re-loadable
batteries.
The outcome of patients receiving SCS for PAOD
due to atherosclerosis is quite different. The mortality
is high, but still less than reported in most PAOD
studies.20e22 This difference is attributable to the
selection procedure that excludes the patients with
a poor life expectancy as well as those with rapidly
progressive ischemic necrosis, wet gangrene orEur J Vasc Endovasc Surg Vol 33, June 2007
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however, the long-term non-survivors who could re-
tain a functional leg until the end of their life still
greatly benefited from SCS treatment.
Unexpectedly, SCS did not perform significantly
better in stage III than in stage IV patients, most prob-
ably because the selection procedure tends to exclude
patients with the worse microcirculatory condition.
When feasible, SCS appears definitely superior to
conservative treatment in terms of mid and long-
term limb survival. A recent review of 20 publications
including over 6000 CLI patients found an over 70%
limb amputation rate within 1 year among those
treated conservatively.22 This value contrasts strongly
with the around 80% one-year limb survival obtained
by SCS in both the present and other recent
studies.6,7,10,15,23 Less benefit, however, was found in
SCS trials having not used microcirculatory selection
criteria,24e27 probably because these studies have
included patients with irreversible microcirculatory
lesions and, hence, no tissue healing potential.
After 1, 3 and 5 years of SCS limb salvage was sim-
ilar to that of infrainguinal reconstructions28,29 and the
number of re-interventions was comparable to that of
large vascular surgical series.30,31 However both tech-
niques cannot be compared, especially because SCS
was never meant to be an alternative technique to re-
constructive procedures, even in the very few patients
who could have benefit from both techniques. Fur-
thermore, reports on reconstructive procedures
include a variable proportion of Fontaine’s stage ll
patients in which SCS has no proven benefit as well
as a large number of patients in the most severe stage
of the disease, who are beyond SCS treatment
capabilities.
In the long run the functional results of SCS are cer-
tainly inferior to those of successful reconstructive
procedures. Several studies32e34 have pointed out
the importance of functional outcomes measures after
lower extremity revascularization. However, it was
also found that instruments to measure these out-
comes are difficult to administer to an elderly popula-
tion because of the complexity of the rating scales, and
because many questions in standard questionnaires
do not pertain to the activities of older adults.35 In-
deed no firm data could be gained in this study on
walking distances because most patients were unable
to perform treadmill tests. The Walking Impairment
Questionnaire36 was considered inappropriate in the
presence of multiple confounding factors such as
severe musculo-skeletal, heart and lung diseases.
Nevertheless, most of these rather aged and sedentary
SCS responders declared themselves satisfied with
a walking distance of several hundred meters. TheseEur J Vasc Endovasc Surg Vol 33, June 2007patients compare favorably with the 46% of patients
who are still nonambulatory 17 months after a
below-knee amputation.37 Notable decrease over time
of the walking capacity was only observed in the
few patients who finally required a late amputation
and in almost every case of system dysfunction.
Severe rest pain commonly recurred at the time of
battery depletion, or of accidental system dysfunction;
it always disappeared shortly after correction of the
failure. This observation confirms that clinical im-
provement is due to SCS, and that the delivery of an
adequate electrical current at the right spinal level is
essential to keep its pain relieving effect.
Several experimental and clinical studies have con-
cluded to a beneficial effect of SCS on the microcircu-
lation of ischemic and non-ischemic tissues.1,3,8,26,38 In
the present study, after having increased during
roughly 3 months, the tcpO2 values remained at the
same stable level over time in the large majority of
patients who did not require a late amputation. This
stable enhancement of tcpO2 over time strongly sug-
gests that lasting microcirculatory changes are respon-
sible for the long-term benefits reported by most
treatment responders. However, tcpO2 measurements
being notoriously influenced by uncertain changes
occurring in the heart and lung functions as well as
in the texture of the skin and subcutaneous tissue,
comparisons between tcpO2 values gained at wide
intervals cannot be considered absolutely conclusive.
The necessity of re-interventions over time is
a well-known major drawback of SCS treatment. In
the present study re-interventions were more frequent
than in other SCS trials.19,39,40 This difference is
mostly attributable to normal battery replacements
that account for half of the re-interventions. Most of
these re-interventions were performed after periods
of time that are largely beyond the scope of trials
with a shorter follow-up. These re-interventions had
minimal consequences on the patient’s overall condi-
tion. There were only 2 late electrode displacements
and one late rupture. All occurred in patients with
a previous controlateral limb amputation. Because
the frequent torsion movements occurring in the spine
of amputees in their daily lives, especially during
transfers, it seems advisable to use an open surgical
technique to implant electrodes in such cases.
Limitations of the study
The main limitation of this study is inherent to the
indications to SCS treatment: Randomization is
impossible because SCS is exclusively proposed to
patients in whom both invasive and conservative
treatments have already failed.
723Long-term Outcomes of SCSBecause the many confounding problems related to
the older age of the patients -mostly social isolation,
depression and worsening of co-existent diseases- it
was not possible to reliably assess the impact of SCS
treatment on QOL outcomes.
Finally this study has neither been designed to pro-
vide early and mid-term data nor to test SCS applica-
bility in CLI. Accordingly only limited comparisons
can be made with results obtained with other kinds
of treatment.
In conclusion, the present study has shown that the
initial benefits of SCS treatment persist over time.
High rates of re-interventions were required to main-
tain the benefit of SCS. The systematic use of micro-
circulatory tests has allowed identifying the tiny
proportion of patients who have a fair chance to ben-
efit from SCS treatment at the mid- and long-terms.
Therefore, SCS for clinical limb ischemia must be
regarded a true vascular treatment that definitely
requires the competence of a skilled vascular labora-
tory and of vascular specialists.
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